Senti Biosciences Holdings, Inc.
SNTIHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeSenti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable. The company carries a $5.9M market cap, placing it firmly in the micro-cap category. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Market Cap
$5.9M
Beta
2.22
P/E (TTM)
—
P/E (Fwd)
-0.20
EPS (TTM)
$-1.72
EPS (Fwd)
$-0.95
ROE
-466.5%
ROA
-65.6%
Cash
$6.6M
Total Debt
$20.2M
Free CF
-$17.1M
52W Change
-91.6%
Annual Financials
Cash vs Debt
Where SNTI stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, SNTI finished 62.86% below its 150-day moving average ($0.70) and 66.23% below its 200-day moving average ($0.77). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SNTI overbought or oversold?
At the October 16, 2026 close, SNTI's RSI(14) was 34.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, SNTI has $6.6M in cash with $20.2M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$17.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -466.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $3.3M (2022) to $22K (2025), a 99% decline worth watching.
A beta of 2.22 means SNTI is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SNTI.